Phaseline

Targets › TBXA2R

TBXA2R (Thromboxane A2 receptor): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 2 Phase 2, 1 Phase 3; Cardiovascular, Immunology, Respiratory; next expected readout Jan 2027.

Receptor for thromboxane A2 (TXA2), a potent stimulator of platelet aggregation. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system. (UniProt, P21731)

Open in Phaseline: the race on TBXA2R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
iVascular S.L.U.1-month DAPT
Dual antiplatelet therapy (acetylsalicylic acid + prasugrel or ticagrelor) for 1 month, fo
P2RY12, TBXA2RPhase 3Coronary Artery DiseaseJan 2027
Cumberland PharmaceuticalsIfetroban Sodium
Thromboxane A2 receptor (TP receptor) antagonist
TBXA2RPhase 2Scleroderma, Diffuse; Idiopathic Pulmonary FibrosisJan 2028

Conditions

Coronary Artery Disease (1) Scleroderma, Diffuse (1) Idiopathic Pulmonary Fibrosis (1)

Modalities

small molecule (2)

Companies

iVascular S.L.U. (1) Cumberland Pharmaceuticals (1)

Related targets

P2RY12 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.